Claims for Patent: 8,257,969

Summary for Patent: 8,257,969

Title:	Genetic suppression and replacement
Abstract:	The invention relates to gene suppression and replacement. In particular, the invention relates to enhanced expression of suppression agents for suppressing gene expression in a cell and in vivo and replacement nucleic acids that are not inhibited by the suppression agent. Regulatory elements are included in expression vectors to optimize expression of the suppression agent and/or replacement nucleic acid.
Inventor(s):	Farrar; Gwyneth Jane (Co Dublin, IE), Millington-Ward; Sophia (Dublin 9, IE), Chadderton; Naomi (Dublin 4, IE), Palfi; Arpad (Co Wicklow, IE), O\'Reilly; Mary (Co Dublin, IE), Kenna; Paul (Dublin 7, IE), Humphries; Peter (Co Dublin, IE)
Assignee:	The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth (Dublin, IE) N/A (N/A)
Application Number:	12/595,080
Patent Claims:	1. An enhanced viral expression vector comprising (i) conserved region B from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NO: 93, and optionally (ii) at least one of the conserved regions selected from conserved region C from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NO: 94; conserved region F and G from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NO: 97; and conserved region A from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NO: 92. 2. The vector according to claim 1, wherein the vector additionally comprises: (i) conserved region D from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NO: 95; and/or (ii) at least one of conserved regions H and I from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NOs: 98 and 99 respectively. 3. The vector according to claim 1, wherein the vector comprises at least one of each of conserved regions B, C, D, E, F and G, H, I and A, from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NOs: 93, 94, 95, 96, 97, 98, 99 and 92. 4. The vector according to claim 1, wherein the viral vector is an AAV vector. 5. The vector according to claim 1, wherein the vector comprises at least one sequence selected from the group consisting of a stuffer, an insulator, a silencer, an intron sequence, a post translational regulatory element, a transcription factor binding site, and an enhancer. 6. The vector of claim 5, wherein said sequence(s) is: (i) an enhancer selected from the group consisting of SEQ ID NOs: 87-89 and 91; or (ii) a sequence selected from the group consisting of SEQ ID NOs: 402-413. 7. The vector according to claim 5, wherein the vector comprises at least one transcription factor binding site sequence selected from the group consisting of SEQ ID NOs: 100-401. 8. The vector according to claim 1, wherein the vector comprises a chromatin opening element and/or a sequence encoding a neurotrophic or neuroprotective factor. 9. The vector according to claim 1, wherein the vector comprises at least one suppression agent and/or at least one replacement nucleic acid. 10. The vector according to claim 1, wherein the replacement nucleic acid encodes a rhodopsin gene. 11. The vector according to claim 1, wherein said vector comprises at least one suppression agent, wherein said suppression agent comprises: (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 414, 415, 416, 417, 418, 419, 420 and 421; (ii) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33; or (iii) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 35-67. 12. The vector according to claim 1, wherein said vector comprises at least one replacement nucleic acid, wherein said replacement nucleic acid comprises: (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 68; or (ii) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 76, 78, 80, 82, 84, and 86. 13. The vector according to claim 11, wherein said vector comprises at least one replacement nucleic acid, wherein said replacement nucleic acid comprises: (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 68; or (ii) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 76, 78, 80, 82, 84, and 86. 14. A composition comprising at least one vector according to claim 1. 15. A cell comprising the vector of claim 1. 16. A method of suppressing the expression of a mutant gene and replacing expression of the mutant gene with a replacement nucleic acid, the method comprising the steps of administering to a mammal the composition of claim 13. 17. A kit comprising (i) the vector according to claim 11 and (ii) the vector according to claim 12. 18. The vector according to claim 1, wherein the vector comprises each of conserved regions B and C from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NOs: 93 and 94. 19. The vector according to claim 1, wherein the vector comprises (i) at least one of each of conserved regions B, C, D, F and G from the rhodopsin gene having the nucleic acid sequence set forth in SEQ ID NOs: 93, 94, 95, and 97; (ii) the nucleic acid sequence having the nucleic acid sequence set forth in SEQ ID NO: 411; (iii) the enhancer having the nucleic acid sequence set forth in SEQ ID NO: 91; and (iv) replacement nucleic acid having the nucleic acid sequence set forth in SEQ ID NO: 76. 20. A kit comprising (i) the vector according to claim 19 and (ii) a vector comprising a suppression agent comprising a nucleotide sequence having the nucleic acid sequence set forth in SEQ ID NO: 75.

Details for Patent 8,257,969

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-04-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-04-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-04-12